Thermo Fisher Scientific's Chairman, President, and CEO Marc Casper recently emphasized the strategic significance of the company's acquisition of Sanofi’s sterile injectable manufacturing site in New Jersey, calling it a "great addition" to Thermo Fisher’s global pharmaceutical services network.

The 226,000-square-foot facility, located in New Jersey, was part of a deal announced earlier this year in which Thermo Fisher acquired the site and entered a long-term agreement to continue producing Sanofi’s key medicines. The site houses more than 600 employees and has capabilities in aseptic filling, inspection, labelling, and packaging.

“This acquisition strengthens our capacity to support growing demand for critical injectable medicines while providing continuity for Sanofi’s essential healthcare products,” said Casper. “It aligns with our strategy of expanding our pharma services capabilities and reinforces our commitment to reliable, high-quality manufacturing.”

Thermo Fisher has been actively expanding its contract development and manufacturing organization (CDMO) services to cater to rising demand in sterile injectables, a segment that continues to grow due to its role in chronic and acute disease management, especially in oncology and biologics.

Casper highlighted that the integration of the Sanofi site complements Thermo Fisher’s existing operations and enhances its ability to serve clients from clinical development through to commercial production.

The deal reflects Thermo Fisher’s broader strategy of investing in flexible, end-to-end pharma services infrastructure to meet the increasing global demand for complex injectable therapies.